Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, congratulates Cara Therapeutics ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™July 19, 2018 8:00 AM Cara Therapeutics (CARA) Prices 4.5M Share Common Offering at $19/ShJuly 19, 2018 5:49 AM Pre-Open Stock Movers 7/18: (CHRS) (FNKO) (GWW) Higher; (SAH) (WIN) (HCSG) Lower (more...)July 18, 2018 9:34 AM After-Hours Stock Movers 07/17: (UUUU) (CHRS) (CSX) Higher; (SAH) (HCSG) (TXN) Lower (more...)July 17, 2018 5:58 PM Cara Therapeutics (CARA) Announces Proposed 4.5M Share Common OfferingJuly 17, 2018 4:25 PM